Skip to content

Last week in biopharma partnering: May 8 – 14, 2022

By admin May 16, 2022

Each week (well almost, some weeks are quite uneventful), we compile and curate hot-off-the-press news and updates on the happenings in the world of pharma and life sciences partnering.

Be sure to follow us and keep up-to-date on all things partnering to inform your decisions and strategies.

Pfizer announced acquisition of Biohaven, maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults — see full article.

Aadi Bioscience, Inc., a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced partnerships with prominent next generation sequencing (NGS) providers and leaders in genomic testing and profiling — see full article.

Roche announced extension of alliance with Finland’s Kaiku Health initiated in 2019, partnering on digital health interventions to provide support to people with cancer, focusing initially on tools for patients undergoing cancer immunotherapy — see full article.

Niramai is partnering with Healthians to enable screening facilities – to make women more aware of their breast health and conduct regular screenings as a preventive measure in a non-invasive, painless and privacy-aware manner – in the comfort of their home — see full article.

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced an amendment to its existing financing agreement with Oberland Capital “to progress innovative pipeline” — see full article.

Reports And Markets publishes Global Vaccine Partnering Market Professional Survey Research Report 2022-2028 with analysis and forecasts on the Vaccine Partnering market at the global levels, covering the key regions for growth — get the report.

Monrol Nuclear Products Co. announced that the first patient dose has been completed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited investigational renal cancer therapy product, TLX250 — see full article.

Novo Nordisk partners with venture capital firm Flagship Pioneering, signaling a move away from traditional strategy of generating its pipeline mainly from internal R&D — see full press release.